NIH Funds UAB-Vivo Biosciences Research Team in Vascular Grafts

NIH Funds UAB-Vivo Biosciences Research Team in Vascular Grafts

Vascular Grafts-2
12 cm long vascular graft fabricated at UAB
Vascular Grafts
Electro-spinning apparatus for fabricating graft

NIH-National Center for Advancing Translational Sciences (NCATS) has funded a UAB-Vivo biosciences research team for conducting translational research on vascular grafts led by Principal Investigator Yogesh K. Vohra, PhD. This Phase-I award of $192,314 is under the Small Business Technology Transfer (STTR) program. Approximately 1.4 million surgical procedures that require arterial prostheses are performed annually in the US due to peripheral vascular disease and ischemic heart disease; approximately 500,000 of these are coronary artery bypass operations. The current commercially available synthetic grafts have not been found suitable for small vessel (<6 mm) applications, with a <50% patency rate at 12 months. Disadvantages of prosthetic grafts include increased risk of thrombosis, poor tissue response and integration and poor biomechanics of graft, leading to additional interventions. Because there are no acceptable synthetic prostheses for small-diameter blood vessels, there is a huge demand for tissue engineered vascular grafts, especially small diameter vascular grafts for coronary replacement. The overall goal of this new program is the development and evaluation of a novel functionally-graded biohybrid vascular graft for small diameter for coronary bypass applications.  Tissue engineered vascular constructs developed to date have been engineered mostly using synthetic and animal-derived biomaterials and require pre-seeding of cells before implantation to overcome the complications of prosthetic vascular grafts. However, these biohybrid systems exhibit many limitations including poor cellular adhesion, inadequate biomechanical and functional properties. The UAB research group has recently demonstrated an in vitro regenerated human endothelium on functionally-layered polymeric scaffolds containing bioactive proteins (Figure below).  Moreover, Vivo Biosciences has developed a unique human biomatrix (HuBiogel™) that allows viable tissue constructs by cultivating single or multiple cell types. The research team will combine our functionally-layered graft strategy with this physiological HuBiogel culture technology for fabricating an advanced 3D vascular construct demonstrating enhanced lumen endothelialization and biocompatibility. Our research team includes Dr. Yogesh Vohra (PI, UAB Physics/College of Arts and Sciences) Dr. Vinoy Thomas (UAB MSE/School of Engineering) Dr. Steven Pogwizd (School of Medicine – Cardiovascular Disease)
and Dr. Raj Singh (President -Vivo Biosciences).

Dr. Eugenia Kharlampieva Awarded a NSF Faculty Early Career Development Award

NSF Faculty Early Career Development Award (CAREER)

Eugenia Kharlampieva“CNMB member and a faculty member in the UAB Department of Chemistry Dr. Eugenia Kharlampieva
has been awarded a  National Science Foundation (NSF) Faculty Early Career Development Award entitled “CAREER:  Shape Responses of Ultrathin Hydrogel Microcapsules” for a five year period 2014-2019. This is one of the  National Science Foundation’s most prestigious awards in support of junior faculty who exemplify the role of teacher-scholars through outstanding research, excellent education and the integration of education and research within the context of the mission of their organizations”

Dr. Claudiu T Lungu Awarded a National Institute for Occupational Safety & Health Grant

CNMB Member Dr. Claudiu T Lungu Awarded a National Institute for Occupational Safety & Health Grant (CDC/DHHS R21, Total amount for two years: 09/01/2013 – 08/31/2015: $398,672) 

LunguThe goal of this study is to develop a new technique that allows accurate sampling of gases and vapors at low levels.

Dr. Lungu is investigating a new process of using pulsed visible light to release chemicals from new substrates based on carbon nanotubes. These substrates will be used in air sampling devices for volatile organic compounds and gases for workplace or environmental monitoring. This research could potential lead to a new generation of air samplers that may be faster, cheaper, and more sensitive than the currently available models.

Dr. Eugenia Kharlampieva Awarded a NSF Biomaterials Grant

Dr. Eugenia Kharlampieva Awarded a National Science Foundation Biomaterials Grant
Immunomodulatory Ultrathin Multilayer Coatings for Pancreatic islet Transplantation NSF-DMR1306110, program of Biomaterials (BMAT)
Eugenia KharlampievaThis grant will supports the development of a novel type of cytoprotective material with controlled immunomodulatory and inflammatory responses to be used for cell-basedtransplantation therapy for diabetic recipients. This project is in collaboration between departments of Chemistry (Eugenia Kharlampieva, PI) and Microbiology (Hubert Tse, coPI).  Although transplantation of pancreatic islet cells has emerged as a promising treatment for Type 1 diabetes, its clinical application remains limited due to adverse effects of immunosuppression and declining allograft function. The awarded project will develop a preclinical approach to preserve islet viability and function during culturing and transplantation by protecting pancreatic islets (cell clusters) with a novel polymer coating. These coatings will be designed through hydrogen-bonded assembly of cytocompatible macromolecules with antioxidant and anti-inflammatory characteristics.  This project is particularly timely since current islet encapsulation systems are challenging for transplantations due to high cytotoxicity and the requirement for large injection volumes. The design of novel immunoprotective materials will open new prospects for developing biomaterials with unique characteristics having applications in various bio-related areas such as bioengineering and tissue engineering. The awarded project will develop interdisciplinary collaborative research which should stimulate awareness of the needs of the UAB biomedical research community for specialized polymer-based biomaterials as novel platforms for cell transplantation therapy.

NIH, Vista Engineering and UAB CNMB

NIH Issues a Small Business Technology Transfer Phase II Award to Vista Engineering and UAB CNMB Scientists

National Institute of Dental and Craniofacial Research (NIDCR) has issued a two-year commercialization award entitled “Nanotechnology Enabled Temporomandibular Joint (TMJ) Prosthesis” to a Birmingham based company Vista Engineering and UAB CNMB researchers (Vista PI Dr. Raymond Thompson and UAB PI Dr. Yogesh Vohra, Dr. Aaron Catledge, and Dr. Patrick Louis).

This award of $746,369 is for a two-year period starting August 15th, 2011. It is estimated that over 10 million people in the United States experience pain and dysfunction in and near the TMJ. Typical symptoms include facial and jaw joint pain, neck and shoulder pain, headaches, locking of the jaw, and limited opening or inability to open the mouth comfortably. The vast majority of these patients can be treated with conservative, non-invasive therapies. However, some patients with severe TMJ degeneration may require a prosthetic replacement. Implants have been used primarily to replace the articular disc of the joint and the condylar head of the mandible. However, long-term success and functioning of these implants remains a serious problem.

Major factors contributing to the failure of TMJ devices include the choice of the design and materials of the implant, and the production of wear particles that can trigger a cascade of events that ultimately may result in the damage to TMJ structures. CNMB scientists and Vista engineering have been exploring the use of nanostructured diamond coatings on metallic components of TMJ to lower mechanical wear and improve clinical outcomes. The goal of this STTR Phase II program is to design a minimally invasive diamond-on-diamond articulating TMJ device using computational modeling approaches. This next generation of TMJ device will be fabricated and tested in a TMJ wear-simulator to have a service lifetime of more than ten-years of clinical use. The TMJ devices that show lowest mechanical wear in simulator studies will also be tested in an animal model. The clinical translational studies are planned to eventually allow testing of new TMJ devices for human use in the next few years.

From CNMB archives